Alvotech

NasdaqGM:ALVO

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Pharmaceuticals

Location

Iceland

Market Cap

USD 2.89 B

Share Price

USD 9.35

Avg Daily Volume

189,212

Change (1 day)

3.77%

Change (1 year)

-30.79%

Change (YTD)

-29.33%

Alvotech Dividend Yield on June 20, 2025: 0.00%

Alvotech Dividend Yield is 0.00% on June 20, 2025. Dividend yield measures the dividend per share relative to stock's price value; higher yield suggests higher dividend return.

Alvotech 52-week low Dividend Yield is 0.00% on June 20, 2025, which is NA below the current Dividend Yield.
Alvotech 52-week low Dividend Yield is 0.00% on June 20, 2025, which is NA below the current Dividend Yield.
Alvotech average Dividend Yield for the last 52 weeks is 0.00%.

Daily

From:

To:

Zoom:

Key data

Date	Dividend Yield	Market Capitalization	Share Price	Share Price

NasdaqGM: ALVO

Alvotech

CEO	Mr. Robert Wessman
IPO Date	June 16, 2022
Location	Iceland
Headquarters	Saemundargata 15-19
Employees	1,012
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Pharmaceuticals

Description

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.